Targeting glutamine metabolism in PIK3CA mutant colorectal cancers

被引：13

作者：

Feng, Xiujing

Hao, Yujun

Wang, Zhenghe ^{[1
]}

机构：

[1] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA

来源：

GENES & DISEASES | 2016年 / 3卷 / 04期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/j.gendis.2016.09.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We recently reported that PIK3CA mutant colorectal cancers (CRCs) are addicted to glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhibitor suppresses in vivo growth of PIK3CA mutant, but not wild-type, CRCs. This study indicates that targeting glutamine may be an effective approach to treat CRCs with PIK3CA mutations. Copyright (C) 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：241 / 243

页数：3

共 50 条

[31] The Landscape of PIK3CA Mutations in Colorectal Cancer
Voutsadakis, Ioannis A.
[J]. CLINICAL COLORECTAL CANCER, 2021, 20 (03) : 201 - 215
[32] Aspirin and PIK3CA Mutations in Colorectal Cancer
Kirstein, M. M.
Vogel, A.
[J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (03): : 306 - 307
[33] The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
Voutsadakis, Ioannis A.
[J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
[34] Murine-derived colorectal cancer organoid culture high-throughput drug screening to identify novel combinations targeting PIK3CA mutant cancers
DeZeeuw, Alyssa K.
DeStefanis, Rebecca A.
Sha, Gioia
Pasch, Cheri A.
Clipson, Linda
Deming, Dustin A.
[J]. CANCER RESEARCH, 2020, 80 (16)
[35] PIK3CA alterations in Middle Eastern ovarian cancers
Jehad Abubaker
Prashant Bavi
Wael Al-Haqawi
Zeenath Jehan
Adnan Munkarah
Shahab Uddin
Khawla S Al-Kuraya
[J]. Molecular Cancer, 8
[36] PIK3CA alterations in Middle Eastern ovarian cancers
Abubaker, Jehad
Bavi, Prashant
Al-Haqawi, Wael
Jehan, Zeenath
Munkarah, Adnan
Uddin, Shahab
Al-Kuraya, Khawla S.
[J]. MOLECULAR CANCER, 2009, 8
[37] PIK3CA mutant tumors depend on oxoglutarate dehydrogenase
Ilic, Nina
Birsoy, Kivanc
Aguirre, Andrew J.
Kory, Nora
Pacold, Michael E.
Singh, Shambhavi
Moody, Susan E.
DeAngelo, Joseph D.
Spardy, Nicole A.
Freinkman, Elizaveta
Weir, Barbara A.
Tsherniak, Aviad
Cowley, Glenn S.
Root, David E.
Asara, John M.
Vazquez, Francisca
Widlund, Hans R.
Sabatini, David M.
Hahn, William C.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (17) : E3434 - E3443
[38] PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
Janku, Filip
Wheler, Jennifer J.
Naing, Aung
Stepanek, Vanda M.
Falchook, Gerald S.
Fu, Siqing
Garrido-Laguna, Ignacio
Tsimberidou, Apostolia M.
Piha-Paul, Sarina A.
Moulder, Stacy L.
Lee, J. Jack
Luthra, Rajyalakshmi
Hong, David S.
Kurzrock, Razelle
[J]. ONCOTARGET, 2012, 3 (12) : 1566 - 1575
[39] Frequency and Clinicopathologic Profile of PIK3CA Mutant GISTs
Felisiak-Golabek, Anna
Wasag, Bartosz
Coates, Tiffany
Lasota, Jerzy P.
Miettinen, Markku
[J]. LABORATORY INVESTIGATION, 2015, 95 : 17A - 17A
[40] Frequency and Clinicopathologic Profile of PIK3CA Mutant GISTs
Felisiak-Golabek, Anna
Wasag, Bartosz
Coates, Tiffany
Lasota, Jerzy P.
Miettinen, Markku
[J]. MODERN PATHOLOGY, 2015, 28 : 17A - 17A

← 1 2 3 4 5 →